ASTRUM: ANNUAL REPORT 2023
Astron Finance (08333.HK): Net loss of HK$9.562 million in 2023
Glonghui, March 22丨Astron Finance (08333.HK) announced that for the year ended December 31, 2023, it achieved revenue of HK$14.464 million, an increase of 66.2% over the year; the company owner should have accounted for a loss of HK$9.562 million during the year, and the company owner should have accounted for a loss of HK$34.116 million during the same period last year, with a basic and diluted loss of HK9.96 HK cents per share
ASTRUM: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Astron Finance (08333) issued a profit warning and expects a net loss of no less than HK$9.5 million in 2023
According to the Zhitong Finance App, Asteran Finance (08333) announced that compared with the net loss of approximately HK$34.1 million for the year ended December 31, 2022 (2022), the Group expects to achieve a net loss of no less than HK$9.5 million in 2023. The decrease in expected net loss for 2023 is mainly due to a sharp increase in earnings from approximately HK$8.7 million in 2022 to approximately HK$14.5 million in 2023; and net loss of unconfirmed payment agreements in 2023 (2022: approximately HK$18.2 million).
ASTRUM: THIRD QUARTERLY REPORT 2023
ASTRUM: THIRD QUARTERLY RESULTS ANNOUNCEMENT FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2023
ASTRUM: INTERIM REPORT 2023
ASTRUM: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2023
ASTRUM: NOTICE OF BOARD MEETING
Dr. Kang Sun Speaks at University of Michigan Unveiling of Its "Astrum" Solar Car Powered by Amprius Batteries
ASTRUM: FIRST QUARTERLY REPORT 2023
ASTRUM: FIRST QUARTERLY RESULTS ANNOUNCEMENT FOR THE THREE MONTHS ENDED 31 MARCH 2023
AstraZeneca Finance: An update on financial performance
AstraZeneca Finance (08333): A recent fake mobile app with a company logo in a short video has nothing to do with the company
According to the Zhitong Finance App, AstraZeneca Finance (08333) announced that the company has recently noticed that some lawbreakers have recently invited the public to download mobile apps to register on the investment platform through a short video social media platform in the People's Republic of China. The fake mobile app bears the company logo and contains content purporting to be related to AstraZeneca Asset Management Co., Ltd., a wholly-owned subsidiary of the company. The Group has nothing to do with the fake mobile app. The fake mobile app is not owned or operated by the Group, and there may also be other fake mobile apps and/or websites claiming to be related to the company, and the company is not
AstraZeneca Finance: Annual Report 2022
AstraZeneca Financial (08333) announced its 2022 results, with a net loss of HK$34.116 million, an increase of 284.5% over the previous year
According to the Zhitong Finance App, AstraZeneca Financial (08333) announced its results for the year ended December 31, 2022, with earnings of HK$8.75,000, a year-on-year decrease of 32.6%; net loss of HK$34.116 million, an increase of 284.5% over the previous year; and a basic loss of HK$30.49 per share. The year-on-year decline in the Group's total revenue for the year was mainly due to a sharp decrease in commission income from brokerage services and placement and underwriting services and interest income from securities and initial public offering financing.
AstraZeneca Financial: Annual Results Announcement for the Year Ended December 31, 2022
AstraZeneca Financial (08333.HK) Earnings: Expected annual net loss of not less than HK$34 million
Gelonghui, Feb. 27 丨 AstraZeneca Financial (08333.HK) announced that compared with the net loss of approximately HK$8.9 million for the year ending 31 December 2021, the Group expects to record a net loss of no less than HK$34 million in 2022. The anticipated increase in net loss in 2022 is mainly due to (a) a sharp decrease in earnings from approximately HK$12.9 million in 2021 to approximately HK$8.7 million in 2022; (b) no confirmation of fair value returns on put and repurchase options associated with an investment in an associated company in 2022 (2021: about 2)
AstraZeneca Financial (08333.HK) “10 in 1” stock merger takes effect today
On December 21, 2022, AstraZeneca Finance (08333.HK) announced that on December 21, 2022, issued and unissued shares with a face value of HK$0.01 per 10 shares were merged into 1 consolidated share with a face value of HK$0.1 per share. The company has a balance of 9.6 million shares.
AstraZeneca Finance (08333): The share merger will take effect on December 21
According to the Zhitong Finance App, AstraZeneca Finance (08333) issued an announcement that the share merger will take effect on December 21, 2022 (Wednesday). Consolidated share trading on the Stock Exchange will commence at 9:00 a.m. on December 21, 2022 (Wednesday). As a result of the share merger and the share option plan, the number of consolidated shares to be issued as a result of the exercise of unexercised share options will be adjusted to 6.8 million shares as a result of the effective date of the share merger. The exercise price for each consolidated share is HK$0.96.
No Data